AFTER an independent report upheld some of Azeem Rafiq's allegations, Yorkshire have issued 'profound apologies' to the former player of the county.
In a statement, Yorkshire said Rafiq was "the victim of inappropriate behaviour", which they have described as "clearly unacceptable".
But in response, Rafiq has accused the county of "fudging" his claim of institutional racism.
After the former player had alleged he suffered racist behaviour during his time at the club that also pushed him feeling suicidal - an independent investigation was commissioned by Yorkshire last September.
The panel of experts comprising of experts from the field of HR, sport, governance and employment law - submitted a final finding report to the club last weekend along with recommendations.
Yorkshire stopped short of any admission of Rafiq's central claim of racism, but conceded on Thursday (19) that "several of the allegations made by Azeem were upheld".
Yorkshire said in a statement: "There were many allegations made against the club, most of which relate to a period more than 10 years ago.
"Many of the allegations were not upheld and for others there was insufficient evidence for the panel to make a determination.
"It is right, however, to acknowledge from the outset that several of the allegations made by Azeem were upheld and that sadly, historically, Azeem was the victim of inappropriate behaviour.
"This is clearly unacceptable. We would like to express our profound apologies for this.
"The Panel also found that the club failed to implement its policies and procedures in relation to these serious issues.
"The club understands the importance of the Panel's findings."
Reacting to Yorkshire's announcement, Rafiq said on Twitter: "'Inappropriate behaviour' are you sure about that @YorkshireCCC?? You carry on playing with your words & fudging this best way possible. ITS NOT GOING AWAY!!"
Rafiq was a former England U19 captain who also captained Yorkshire in a Twenty20 match in 2012.
Roger Hutton, appointed Yorkshire chair last year, issued a personal apology to Rafiq and said: "I would like to acknowledge Azeem's courage in raising these issues, and his participation in the investigation, which I understand must have been very difficult.
"I would also like to express my sincere apology to him for certain failings by the club, which have been highlighted by the panel.
"He has very obviously experienced some difficult and distressing times during the time since 2008 and the club could, and should, have supported him better.
"Since I joined the board in 2020, it has become obvious to me that both prior to and since, it has continually tried to improve its relationship with diverse communities.
"It has however not progressed far enough, particularly as we learn to see the world from fresh eyes, and I consider that this report will be a platform for further important changes at Yorkshire County Cricket Club."
Before the release of the final report, Rafiq speaking to Sky Sports on Wednesday (18) said the "last 12 months has been harrowing".
Ian Watmore, the ECB's chair, said the governing body was looking forward to receiving a "copy of the report promptly" so it could decide what action is necessary.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.